Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript

Lucid Diagnostics reported Q2 2026 results showing modest revenue growth and continued attention to reimbursement opportunities. Revenue reached $1.5 million, up 17% from the prior quarter, while EsoGuard test volume totaled 2,770 tests, within the company’s target range of 2,500 to 3,000. Cash and cash equivalents were $33.4 million as of June 30, 2026, remaining flat after a recent common stock financing. The company raised $16.8 million in net proceeds from a stock offering during the quarter to support commercialization and market access. GAAP net loss attributable to common stockholders was $14.7 million, or $0.08 per share, including a $3 million deemed preferred stock dividend. Non-GAAP adjusted loss was $0.06 per share, a slight sequential improvement.